Aquestive Therapeutics (AQST) Revenue (2017 - 2026)

Aquestive Therapeutics' Revenue history runs 10 years deep, the most recent figure standing at $14.4 million for Q1 2026.

• In Q1 2026, Revenue rose 65.67% year-over-year to $14.4 million; the TTM figure through Mar 2026 stood at $6.7 million (down 87.71% YoY), while the FY2025 annual figure was $938000.0, down 98.37% from the prior year.
• Revenue was $14.4 million for Q1 2026 at Aquestive Therapeutics, up from -$30.6 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $20.1 million in Q2 2024 to a low of -$30.6 million in Q4 2025.
• Historically, Revenue has averaged $9.8 million across 5 years, with a median of $12.1 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Revenue jumped 300.0% in 2022, then slumped 357.79% in 2025.
• A 5-year view of Revenue shows it stood at $10.7 million in 2022, then increased by 23.63% to $13.2 million in 2023, then fell by 10.14% to $11.9 million in 2024, then sank by 357.79% to -$30.6 million in 2025, then jumped by 147.22% to $14.4 million in 2026.
• The last three Revenue figures came in at $14.4 million (Q1 2026), -$30.6 million (Q4 2025), and $12.8 million (Q3 2025), per Business Quant data.